Home » Author Archive

Bank of America Cuts Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $25.00

Posted by Matthew Jenks on Jan 8th, 2025

Day One Biopharmaceuticals (NASDAQ:DAWN – Free Report) had its price target cut by Bank of America from $28.00 to $25.00 in a report published on Tuesday,Benzinga reports. They currently have a buy rating on the stock. Several... More of this article »

Financial Survey: Saul Centers (NYSE:BFS) & Safehold (NYSE:SAFE)

Posted by Matthew Jenks on Jan 8th, 2025

Safehold (NYSE:SAFE – Get Free Report) and Saul Centers (NYSE:BFS – Get Free Report) are both small-cap finance companies, but which is the superior investment? We will contrast the two companies based on the strength of... More of this article »

TruBridge (NASDAQ:TBRG) versus Infosys (NYSE:INFY) Financial Review

Posted by Matthew Jenks on Jan 8th, 2025

TruBridge (NASDAQ:TBRG – Get Free Report) and Infosys (NYSE:INFY – Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst... More of this article »

Microbot Medical (NASDAQ: MBOT) Enters into ATM Agreement; Provides Intellectual Property UpdateMicrobot Medical Inc. recently disclosed the details of the At-the-Market Offering Agreement (ATM Agreement) entered into with H.C. Wainwright & Co. LLC.

Posted by Matthew Jenks on Jan 8th, 2025

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Microbot Medical’s 8K filing here. About Microbot Medical (Get Free Report) Microbot... More of this article »

Barclays Upgrades Boeing (NYSE:BA) to Overweight

Posted by Matthew Jenks on Jan 8th, 2025

Boeing (NYSE:BA – Get Free Report) was upgraded by analysts at Barclays from an “equal weight” rating to an “overweight” rating in a research note issued on Monday, MarketBeat.com reports. The brokerage... More of this article »